ALNYLAM PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2021-12-21

Reporting Person: MARAGANORE JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-21	Common Stock	A	14167	$0.0	Acquired	234299	Direct
2021-12-22	Common Stock	F	6315	$189.13	Disposed	227984	Direct
2021-12-22	Common Stock	F	2	$190.5	Disposed	227982	Direct
2021-12-22	Common Stock	F	319	$186.02	Disposed	227663	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3133	Indirect

Footnotes

F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.

F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.